
Cannabis
Oral cannabis did not affect dyskinesia in Parkinson's disease
Neurology. 2004 Oct 12;63(7):1245-50.19 patients with Parkinson's disease and levodopa-induced dyskinesia completed a 4-week oral cannabis dose-escalation study followed by a randomized crossover trial of cannabis versus placebo (4 weeks each phase). The primary outcome was the Unified Parkinson's Disease Rating Scale dyskinesia score. There was no evidence of any effects on Parkinson's or dyskinesia symptoms. Cannabis was well-tolerated.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.